Calliditas Therapeutics’ Setanaxib Study: A New Hope for Alport Syndrome

Calliditas Therapeutics Ab ((CALT)) announced an update on their ongoing clinical study.

Study Overview: Calliditas Therapeutics AB is conducting a Phase 2a clinical study titled A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the NOX1/4 Inhibitor Setanaxib in Patients With Alport Syndrome. The study aims to assess the safety and efficacy of setanaxib, a NOX1/4 inhibitor, in patients with Alport syndrome, a genetic condition affecting kidney function. This study is significant as it explores a potential new treatment option that could enhance the current standard of care.

Intervention/Treatment: The study is testing setanaxib, an experimental drug designed to inhibit the NOX1/4 enzymes, alongside a placebo. Setanaxib is intended to preserve kidney function when used in conjunction with standard treatments for Alport syndrome.

Study Design: This interventional study follows a randomized, parallel assignment model with triple masking (participant, care provider, investigator) to ensure unbiased results. Its primary purpose is to evaluate the treatment’s safety and efficacy.

Study Timeline: The study began on November 27, 2023, and was completed with the last update submitted on July 22, 2025. These dates are crucial for tracking the study’s progress and understanding its current status.

Market Implications: The completion of this study could positively impact Calliditas Therapeutics’ stock performance by potentially introducing a novel treatment for Alport syndrome. Investors may view this as a promising development, especially if the results indicate significant benefits over existing therapies. Competitors in the renal disease treatment market will be closely monitoring these outcomes.

The study is now completed, with further details available on the ClinicalTrials portal.